Search

Your search keyword '"Serretta V."' showing total 651 results
Start Over Author "Serretta V."
651 results on '"Serretta V."'

2. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

Author

Pisano, F., Gontero, P., Sylvester, R., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, A., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P.U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S.F., Xylinas, E., Karnes, R.J., and Palou, J.

Published
2021
Full Text
View/download PDF

4. Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes

Author

Cuccia F, Mortellaro G, Serretta V, Valenti V, Tripoli A, Gueci M, Luca N, Lo Casto A, and Ferrera G

Subjects
prostate neoplasm, radiotherapy, hypofractionation, adjuvant, salvage, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Francesco Cuccia,1,2 Gianluca Mortellaro,2 Vincenzo Serretta,3 Vito Valenti,1,2 Antonella Tripoli,1,2 Marina Gueci,1,2 Nicoletta Luca,1,2 Antonio Lo Casto,4 Giuseppe Ferrera2 1Radiation Oncology School, University of Palermo, Palermo, Italy; 2Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy; 3Section of Urology, Department of Surgical Oncological and Oral Science, University of Palermo, Palermo, Italy; 4Radiation Oncology School, Section of Radiological Sciences, DIBIMED, Università degli Studi di Palermo, Palermo, Italy Purpose: This is a mono-institutional study of acute and late toxicities and early biochemical control of a retrospective series of 75 prostate cancer patients treated with moderate postoperative hypofractionation delivered by helical tomotherapy (HT). Patients and methods: From April 2013 to June 2017, 75 patients received adjuvant (n=37) or salvage (n=38) treatment, delivering to prostate bed a total dose of 63.8 Gy (equivalent dose in 2-Gy fractions=67.4 Gy) using 2.2 Gy fractions. Whole-pelvis irradiation was performed in 63% of cases (median dose, 49.3 Gy; range, 48–55.1 Gy). Concurrent hormonal therapy was administered in 46% of cases. Common Terminology Criteria for Adverse Events (version 4.0) was adopted for acute and late genitourinary (GU) and gastrointestinal (GI) toxicity evaluations. Biochemical progression was defined as PSA level increase of ≥0.2 or more above the postoperative radiotherapy (RT) nadir. Results: Acute GU toxicities were as follows: G1 in 46% and G2 in 4%, detecting no G≥3 events. For GI toxicity, we recorded G1 in 36% and G2 in 18%. With a median follow-up of 30 months (range, 12–58 months), we found late toxicity G2 GI in 6.6% and G≥2 GU in 5.3%, including two patients who underwent surgical incontinence correction. Acute GI≥2 toxicity and diabetes were found to be predictive of late GI≥2 toxicity (P=0.04 and P=0.0019). Actuarial 2- and 3-year biochemical recurrence-free survivals were 88% and 73%, respectively, for the entire population. Conclusion: In our experience, moderate hypofractionated postoperative RT with HT was feasible and safe, with reports of low incidence of toxicity and promising biochemical control rates. Keywords: prostate neoplasm, radiotherapy, hypofractionation, adjuvant, salvage

Published
2018

5. A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer

Author

Valerio M. R., Serretta V., Arico D., Fazio I., Altieri V., Baldari S., Pennisi M., Girlando A., Spada M., Gesolfo C. S., Messina M., Messina C., Giorgia L., Sortino G., Di Grazia A., Guggino R., Borsellino N., Piazza D., Gebbia V., Valerio M.R., Serretta V., Arico D., Fazio I., Altieri V., Baldari S., Pennisi M., Girlando A., Spada M., Gesolfo C.S., Messina M., Messina C., Giorgia L., Sortino G., Di Grazia A., Guggino R., Borsellino N., Piazza D., and Gebbia V.

Subjects
Prostate cancer, adherence to guidelines, multidisciplinary tumor boards, virtualization
Abstract

Background/Aim: At present, multidisciplinary tumor boards (MDTB) are considered best practice in oncology. However, web-based virtualization of MDTB may increase participation in meetings, the number of cases discussed, and adherence to guidelines, deliver better treatment, and eventually improve outcomes for patients with prostate cancer. Patients and Methods: This is an observational study focused on exploring the structuring process and implementing a multi-institutional virtual MDTB in Sicily, Italy. Other endpoints included the analysis of cooperation between participants, adherence to guidelines, patient outcomes, and patient satisfaction. Results: Overall, 126 patients were referred to the virtual MDTB for a total of 302 cases discussed in an 18-month period. Nearly 45% of cases were referred from general hospitals or tertiary centers, 38% from comprehensive cancer centers, and only 17% from academic ones. Most health professional participants (95%) reported eliminating geographical barriers and consequently reducing costs and saving time as key advantages of virtual meetings over face-to-face ones. Using a specifically designed platform for virtual MDTBs was another excellent point, especially to geolocate clinical trials and time-lapse data storage. The majority of referred patients had stage T 3-4 prostate cancer (79%). Overall, 71% of proposals discussed were approved unchanged, while 19% changed after the virtual MDTB discussion. Debated points were mostly radiologic, surgical, medical, or radiation treatment-related issues. In particular, the prescriptive appropriateness of positron emission tomography with 68Ga-prostatic specific membrane antigen, newer drugs, radiation versus surgical approach, stage T3-4 cases, and adjuvant therapy represented the most debated issues. The proposed diagnostic and/or therapeutic options were controlled for adherence to the guidelines and/or updated scientific evidence. Overall, 98% of approved proposals and changes were in line with the guidelines. Overall, most participants felt virtual MDTB was very useful and case discussions led to a major change of strategy in 19% of cases. Conclusion: Virtual MDTBs are a very useful way to achieve best management of prostate cancer while saving time and fostering cooperation.

Published
2022

6. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Author

Soria, Francesco, Pisano, Francesca, Gontero, Paolo, Palou, J., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, J. A., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P. U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S. F., Xylinas, E., Karnes, R. J., and Sylvester, R.

Published
2018
Full Text
View/download PDF

7. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

Author

Palou, J., Pisano, F., Sylvester, R., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, A. J., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P. U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E. K., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S. F., Xylinas, E., Karnes, R. J., and Gontero, P.

Published
2018
Full Text
View/download PDF

9. Virtual multi-institutional tumor board: Feasibility and physicians acceptance, a GSTU foundation project in Sicily

Author

Serretta, V., primary, Scalici Gesolfo, C., additional, Gebbia, V., additional, Borsellino, N., additional, Di Trapani, D., additional, Ferrera, G., additional, Spada, M., additional, Armenio, A., additional, Lamartina, M., additional, Valerio, M.R., additional, Di Grazia, A., additional, Pennisi, M., additional, Caruso, M., additional, Ruoppolo, M., additional, Barbera, M., additional, Adamo, V., additional, Cimino, S., additional, Firenze, A., additional, Piazza, D., additional, Macchiarella, V., additional, Fazio, I., additional, and La Vecchia, M., additional

Published
2022
Full Text
View/download PDF

11. Possible effectiveness of anti-COVID-19 hygienic measures in preventing hospital acquired infections in urological wards

Author

Baiamonte, D., primary, Biancolini, R., additional, Aimar, R., additional, Abrate, A., additional, Mannone, P., additional, Di Gregorio, G., additional, Tulone, G., additional, Giannone, S., additional, Giaimo, R., additional, Vella, M., additional, Pavone, C., additional, Serretta, V., additional, Dalmasso, E., additional, and Simonato, A., additional

Published
2021
Full Text
View/download PDF

12. Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3

Author

Pisano, F., primary, Gontero, P., additional, Sylvester, R., additional, Joniau, S., additional, Serretta, V., additional, Larré, S., additional, Di Stasi, S., additional, van Rhijn, B., additional, Witjes, A., additional, Grotenhuis, A., additional, Colombo, R., additional, Briganti, A., additional, Babjuk, M., additional, Soukup, V., additional, Malmstrom, P.U., additional, Irani, J., additional, Malats, N., additional, Baniel, J., additional, Mano, R., additional, Cai, T., additional, Cha, E., additional, Ardelt, P., additional, Varkarakis, J., additional, Bartoletti, R., additional, Dalbagni, G., additional, Shariat, S.F., additional, Xylinas, E., additional, Karnes, R.J., additional, and Palou, J., additional

Published
2021
Full Text
View/download PDF

13. The potential role of COVID-19 hygienic measures in reducing infective complications during hospitalization

Author

Baiamonte, D., primary, Biancolini, R., additional, Aimar, R., additional, Mannone, P., additional, Di Gregorio, G., additional, Tulone, G., additional, Giannone, S., additional, Abrate, A., additional, Vella, M., additional, Serretta, V., additional, Pavone, C., additional, Giaimo, R., additional, Dalmasso, E., additional, and Simonato, A., additional

Published
2021
Full Text
View/download PDF

14. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

Author

Pisano, F. Gontero, P. Sylvester, R. Joniau, S. and Serretta, V Larre, S. Di Stasi, S. van Rhijn, B. Witjes, A. Grotenhuis, A. Colombo, R. Briganti, A. Babjuk, M. and Soukup, V Malmstrom, P. U. Irani, J. Malats, N. and Baniel, J. Mano, R. Cai, T. Cha, E. Ardelt, P. and Varkarakis, J. Bartoletti, R. Dalbagni, G. Shariat, S. F. and Xylinas, E. Karnes, R. J. Palou, J.

Abstract

Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR. Material and methods: In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions. Results: The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors >= 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001. The presence of muscle in the specimen was no longer significant, while the presence of CIS only remained significant in the model with tumor size, p < 0.001. Conclusions: The most significant factors for a higher risk of residual disease at re-TUR in T1G3 patients are multifocal tumors and tumors more than 3 cm. Patients with concomitant CIS and those without muscle in the specimen also have a higher risk of residual disease. (C) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.

Published
2021

15. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.

Author

Pisano, F, Gontero, P, Sylvester, R, Joniau, S, Serretta, V, Larré, S, Di Stasi, S, van Rhijn, B, Witjes, A, Grotenhuis, A, Colombo, R, Briganti, A, Babjuk, M, Soukup, V, Malmström, Per-Uno, Irani, J, Malats, N, Baniel, J, Mano, R, Cai, T, Cha, E, Ardelt, P, Varkarakis, J, Bartoletti, R, Dalbagni, G, Shariat, S F, Xylinas, E, Karnes, R J, Palou, J, Pisano, F, Gontero, P, Sylvester, R, Joniau, S, Serretta, V, Larré, S, Di Stasi, S, van Rhijn, B, Witjes, A, Grotenhuis, A, Colombo, R, Briganti, A, Babjuk, M, Soukup, V, Malmström, Per-Uno, Irani, J, Malats, N, Baniel, J, Mano, R, Cai, T, Cha, E, Ardelt, P, Varkarakis, J, Bartoletti, R, Dalbagni, G, Shariat, S F, Xylinas, E, Karnes, R J, and Palou, J

Abstract

INTRODUCTION AND OBJECTIVES: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors that may influence the presence of residual disease at re-TUR. MATERIAL AND METHODS: In our retrospective cohort of 2451 primary T1G3 patients initially treated with BCG, pathology results for 934 patients (38.1%) who underwent re-TUR are available. 74% had multifocal tumors, 20% of tumors were more than 3 cm in diameter and 26% had concomitant CIS. In this subgroup of patients who underwent re-TUR, there was no residual disease in 267 patients (29%) and residual disease in 667 patients (71%): Ta in 378 (40%) and T1 in 289 (31%) patients. Age, gender, tumor status (primary/recurrent), previous intravesical therapy, tumor size, tumor multi-focality, presence of concomitant CIS, and muscle in the specimen were analyzed in order to evaluate risk factors of residual disease at re-TUR, both in univariate analyses and multivariate logistic regressions. RESULTS: The following were not risk factors for residual disease: age, gender, tumor status and previous intravesical chemotherapy. The following were univariate risk factors for presence of residual disease: no muscle in TUR, multiple tumors, tumors > 3 cm, and presence of concomitant CIS. Due to the correlation between tumor multi-focality and tumor size, the multivariate model retained either the number of tumors or the tumor diameter (but not both), p < 0.001.

Published
2021
Full Text
View/download PDF

17. PO-1165: Toxicity and outcomes of postoperative hypofractionated Helical Tomotherapy for prostate cancer

Author

Cuccia, F., primary, Ferrera, G., additional, Serretta, V., additional, Mortellaro, G., additional, Verderame, F., additional, Lupo, A., additional, Cespuglio, D., additional, Ognibene, L., additional, De Gregorio, G., additional, Quartuccio, E., additional, Gioia, A., additional, La Vecchia, M., additional, Luca, N., additional, Trapani, G., additional, Valenti, V., additional, Tripoli, A., additional, and Lo Casto, A., additional

Published
2020
Full Text
View/download PDF

20. Segmental ureterectomy vs radical nephroureterectomy in elderly patients treated for upper tract urothelial carcinoma

Author

Abrate, A., primary, Sessa, F., additional, Sessa, M., additional, Campi, R., additional, Sebastianelli, A., additional, Preto, M., additional, Olivero, A., additional, Varca, V., additional, Benelli, A., additional, Pavone, C., additional, Serretta, V., additional, Vella, M., additional, Brunocilla, E., additional, Serni, S., additional, Trombetta, C., additional, Terrone, C., additional, Gregori, A., additional, Lissiani, A., additional, Gontero, P., additional, Schiavina, R., additional, Gacci, M., additional, and Simonato, A., additional

Published
2020
Full Text
View/download PDF

25. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, Tis bladder cancer

Author

SHARIAT, S, SAGALOWSKY, A, ZIPPE, C, LÜDECKE, G, BOMAN, H, SANCHEZ-CARBAYO, M, CASELLA, R, MIAN, C, FRIEDRICH, M G, EISSA, S, AKAZA, H, SAWCZUK, I, SERRETTA, V, HULAND, H, HEDELIN, H, RUPESH, R, MIYANAGA, N, WIANS, F JR, ROEHRBORN, C G, LOTAN, Y, PERROTTE, P, BENAYOUN, S, SULSER, T, GASSER, T C, MARBERGER, M, and KARAKIEWICZ, P

Published
2004

29. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

Author

Palou, J. Pisano, F. Sylvester, R. Joniau, S. Serretta, V. Larré, S. Di Stasi, S. van Rhijn, B. Witjes, A.J. Grotenhuis, A. Colombo, R. Briganti, A. Babjuk, M. Soukup, V. Malmstrom, P.U. Irani, J. Malats, N. Baniel, J. Mano, R. Cai, T. Cha, E.K. Ardelt, P. Varkarakis, J. Bartoletti, R. Dalbagni, G. Shariat, S.F. Xylinas, E. Karnes, R.J. Gontero, P.

Abstract

Purpose: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. Methods: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model. Results: During a median follow-up of 5.2 years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P < 0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P < 0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen. Conclusions: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2018

30. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Author

Soria, F. Pisano, F. Gontero, P. Palou, J. Joniau, S. Serretta, V. Larré, S. Di Stasi, S. van Rhijn, B. Witjes, J.A. Grotenhuis, A. Colombo, R. Briganti, A. Babjuk, M. Soukup, V. Malmstrom, P.U. Irani, J. Malats, N. Baniel, J. Mano, R. Cai, T. Cha, E. Ardelt, P. Varkarakis, J. Bartoletti, R. Dalbagni, G. Shariat, S.F. Xylinas, E. Karnes, R.J. Sylvester, R.

Abstract

Purpose: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. Methods: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. Results: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1.79, p = 0.001 and HR = 1.53, p = 0.02, respectively). Patients with tumors > 3 cm, multiple tumors or CIS had earlier T3/T4 or N + cystectomies. In patients who progressed, the timing of cystectomy did not affect the risk of T3/T4 or N + disease at RC. Patients with T3/T4 or N + disease at RC had a shorter disease-specific survival (HR = 4.38, p < 0.001), as did patients with CIS at cystectomy (HR = 2.39, p < 0.001). Patients who progressed prior to cystectomy had a shorter disease-specific survival than patients for whom progression was only detected at cystectomy (HR = 0.58, p = 0.024) Conclusions: Patients treated with RC before experiencing progression to muscle-invasive disease harbor better oncological and survival outcomes compared to those who progressed before RC and to those upstaged at surgery. Tumor size and concomitant CIS at diagnosis are the main predictors of surgical treatment while tumor size, CIS and tumor multiplicity are associated with extravesical disease at surgery. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2018

33. The feasibility and prognostic value of sequential evaluation of EGFR cell expression in bladder washings after transurethral resection of Non-Muscle Invasive Bladder Cancer: A new potential tool to identify patients at higher risk of disease progression

Author

Di Maida, F., primary, Mari, A., additional, Gesolfo, C. Scalici, additional, Cangemi, A., additional, Tellini, R., additional, Sforza, S., additional, Cocci, A., additional, Allegro, R., additional, Masieri, L., additional, Russo, A., additional, Carini, M., additional, Minervini, A., additional, and Serretta, V., additional

Published
2019
Full Text
View/download PDF

34. Hypofractionated Helical 3DCRT and IMRT systems for the Post-Operative Treatment of Prostate Cancer: A Mono-Institutional Report

Author

Cuccia, F., primary, Ferrera, G., additional, Serretta, V., additional, Mortellaro, G., additional, Verderame, F., additional, Lupo, A., additional, Cespuglio, D., additional, De Gregorio, G., additional, Quartuccio, E., additional, Luca, N., additional, Trapani, G., additional, Tripoli, A., additional, Valenti, V., additional, and Lo Casto, A., additional

Published
2019
Full Text
View/download PDF

35. Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes

Author

Cuccia, F., primary, Fiorentino, A., additional, Corrao, S., additional, Mortellaro, G., additional, Valenti, V., additional, Tripoli, A., additional, De Gregorio, G., additional, Serretta, V., additional, Verderame, F., additional, Ognibene, L., additional, Lo Casto, A., additional, and Ferrera, G., additional

Published
2019
Full Text
View/download PDF

44. LIMITS OF TRANSURETHRAL RESECTION IN DETECTING UNCOMMON HISTOLOGICAL VARIANTS WITHIN BULKY BLADDER TUMORS IN REAL-LIFE CLINICAL PRACTICE

Author

SCALICI GESOLFO, C., Guarneri, A., Sandro, B., Marco, M., Renzo, C., Matteo, F., Ottavio, D., Simonato, A., Serretta, V., Cristina Scalici Gesolfo, Alessio Guarneri, Sandro Billone, and Marco Moschini, Renzo Colombo, Matteo Ferro, Ottavio DeCobelli, Alchiede Simonato, Vincenzo Serretta

Subjects
bladder cancer, hystotype, rare variants TUR, Settore MED/24 - Urologia
Published
2017

45. Prognostic role of neutrophil-to-lymphocyte ratio in patients with T1G3 non-muscle invasive bladder cancer

Author

Vartolomei, M.D., primary, Ferro, M., additional, Cantiello, F., additional, Lucarelli, G., additional, Di Stasi, S., additional, Guazzoni, G., additional, Busetto, G.M., additional, De Berardinis, F., additional, Rocco, D., additional, Perdona, S., additional, Verze, P., additional, Borghesi, M., additional, Schiavina, R., additional, Almeida, G., additional, Bove, P., additional, Lima, F., additional, Grimaldi, G., additional, Crisan, N., additional, Abu Farhan, A.R., additional, Battaglia, M., additional, Serretta, V., additional, Russo, G.I., additional, Morgia, G., additional, Mirone, V., additional, De Cobelli, O., additional, and Shariat, S.F., additional

Published
2018
Full Text
View/download PDF

46. Kidney sparing surgery for upper tract urothelial carcinoma: Long term results of a multicenter study in comparison with radical nephroureterectomy

Author

Sessa, F., primary, Sebastianelli, A., additional, Abrate, A., additional, Scalici Gesolfo, C., additional, Preto, M., additional, Olivero, A., additional, Varca, V., additional, Benelli, A., additional, Pavone, C., additional, Serretta, V., additional, Vella, M., additional, Brunocilla, E., additional, Serni, S., additional, Trombetta, C., additional, Terrone, C., additional, Gregori, A., additional, Lissiani, A., additional, Gontero, P., additional, Schiavina, R., additional, Simonato, A., additional, and Gacci, M., additional

Published
2018
Full Text
View/download PDF

47. Termino-terminal ureteral anastomosis vs segmental resection of distal pelvic ureter with bladder cuff removal and ureteral reimplantation for urothelial carcinoma of the ureter: A multicenter study

Author

Abrate, A., primary, Sessa, F., additional, Sebastianelli, A., additional, Scalici Gesolfo, C., additional, Preto, M., additional, Olivero, A., additional, Varca, V., additional, Benelli, A., additional, Pavone, C., additional, Serretta, V., additional, Vella, M., additional, Brunocilla, E., additional, Serni, S., additional, Trombetta, C., additional, Terrone, C., additional, Gregori, A., additional, Lissiani, A., additional, Gontero, P., additional, Schiavina, R., additional, Gacci, M., additional, and Simonato, A., additional

Published
2018
Full Text
View/download PDF

49. Kidney sparing surgery vs radical nephroureterectomy for upper tract urothelial carcinoma in patients with vs without renal failure: A multicenter study

Author

Abrate, A., primary, Sessa, F., additional, Sebastianelli, A., additional, Scalici Gesolfo, C., additional, Preto, M., additional, Olivero, A., additional, Varca, V., additional, Benelli, A., additional, Pavone, C., additional, Serretta, V., additional, Vella, M., additional, Brunocilla, E., additional, Serni, S., additional, Trombetta, C., additional, Terrone, C., additional, Gregori, A., additional, Lissiani, A., additional, Gontero, P., additional, Schiavina, R., additional, Gacci, M., additional, and Simonato, A., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results